Novo Nordisk
305.80 DKK
+0.66 %
Less than 1K followers
NOVO B
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
+0.66 %
-3.01 %
-15.17 %
-35.85 %
-51.01 %
-60.91 %
-31.82 %
+48.14 %
+24,462.25 %
Novo Nordisk is a producer of insulin for diabetes treatment. In addition to the specialist expertise in diabetes, the company produces drugs for hormone treatment as well as for hemophilia and bleeding disorders. The products are found on a global market and are sold under separate brands. Novo Nordisk was founded in 1923 and is headquartered in Bagsværd, Denmark.
Read moreMarket cap
1.37T DKK
Turnover
1.88B DKK
Revenue
290.4B
EBIT %
44.19 %
P/E
13.49
Dividend yield-%
3.73 %
Revenue and EBIT-%
Revenue B
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
4.2
2026
Annual report '25
26.3
2026
General meeting '26
All
Research
Press releases
ShowingAll content types
HCA Morgenbørs 02/12 - Mere stabile markeder end i går ovenpå en stærk japansk obligationsauktion
HCA Morgenbørs 01/12 - Rød start på december og fokus på Hafnia og kursmålsændringer
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools



